Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Shares Issued (2017 - 2025)

Historic Shares Issued for Intellia Therapeutics (NTLA) over the last 9 years, with Q2 2025 value amounting to $1.2 million.

  • Intellia Therapeutics' Shares Issued rose 491.94% to $1.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 6109.49%. This contributed to the annual value of $5.9 million for FY2024, which is 1116.84% down from last year.
  • Intellia Therapeutics' Shares Issued amounted to $1.2 million in Q2 2025, which was up 491.94% from $1.0 million recorded in Q4 2024.
  • In the past 5 years, Intellia Therapeutics' Shares Issued registered a high of $1.8 billion during Q3 2021, and its lowest value of -$386.7 million during Q2 2022.
  • Moreover, its 5-year median value for Shares Issued was $1.5 million (2023), whereas its average is $215.0 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Shares Issued soared by 1336875.0% in 2021, and later plummeted by 13316.51% in 2022.
  • Over the past 5 years, Intellia Therapeutics' Shares Issued (Quarter) stood at $1.8 billion in 2021, then crashed by 78.74% to $386.0 million in 2022, then plummeted by 99.74% to $995000.0 in 2023, then increased by 3.52% to $1.0 million in 2024, then rose by 20.1% to $1.2 million in 2025.
  • Its Shares Issued was $1.2 million in Q2 2025, compared to $1.0 million in Q4 2024 and $1.7 million in Q3 2024.